title: Pimecrolimus 1% cream in non-specific inflammatory recurrent balanitis.
abstract: BACKGROUND
  Non-specific balanitis is a common inflammatory dermatosis with frequent relapses and considerable impact on male sexual life.
  
  
  OBJECTIVE
  To evaluate the efficacy and safety of pimecrolimus 1% cream in recurrent non-specific balanitis.
  
  
  METHODS
  Twenty-six patients with recurrent flares of non-specific balanitis were randomly assigned to 1 group applying pimecrolimus cream 1% and 1 group applying placebo on the glans twice daily for 7 days. The patients were assessed on day 14. They were instructed to continue applying the agent whenever symptoms initialized for the following 90 days and take account of the cumulative days with symptoms.
  
  
  RESULTS
  Seven out of the 11 (63.6%) patients in the pimecrolimus group and 1 out of 11 (9%) in the control group were free of all symptoms and lesions after 14 days, 3 (27.3%) in both groups reported improvement, while 1 (9.1%) in the pimecrolimus and 7 (63.6%) in the control group remained unaffected. (chi(2) = 9.0, d.f. = 2, p = 0.011). Days with symptoms during the 90-day follow-up period were 7.50 +/- 3.02 for the pimecrolimus and 17.62 +/- 4.40 for the control group (p = 0.000064).
  
  
  CONCLUSIONS
  Pimecrolimus 1% cream is promising in relieving symptoms and signs of non-specific balanitis during flares and controlling the disease during long-term follow-up.
authors.affiliation: Department of Dermatology, A. Sygros Hospital, University of Athens, Athens, Greece.
authors.forename: S
authors.initials: S
authors.lastname: Georgala
authors.forename: S
authors.initials: S
authors.lastname: Gregoriou
authors.forename: C
authors.initials: C
authors.lastname: Georgala
authors.forename: D
authors.initials: D
authors.lastname: Papaioannou
authors.forename: A
authors.initials: A
authors.lastname: Befon
authors.forename: D
authors.initials: D
authors.lastname: Kalogeromitros
authors.forename: D
authors.initials: D
authors.lastname: Rigopoulos
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D001446:Balanitis / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage; D004311:Double-Blind Method; D004643:Emollients; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome